During the last few months, the cannabis sector has been under pressure and we have been monitoring this trend. The summer tends to be a slow time for the cannabis industry and this year was no different.
This weakness has created a market opportunity and today, we provide you with an update on Relevium Technologies Inc. (RLV.V) (RLLVF). In 2018, the company has made some significant announcements and is in the early innings of a major growth cycle. We are favorable on the continued execution and will monitor how the management team executes from here.
Starts Selling Bioganix on Walmart.com
In late July, Relevium announced a major milestone after it received final listing approval for its Bioganix Gold Series Nutraceuticals on Walmart.com. This approval represents a significant development and we will monitor how this adds value to the company. Relevium immediately started selling its Bioganix Gold Series nutraceutical products and we expect to see the products gain traction. This is the initial introduction to Walmart shoppers through its online platform and the launching pad for the eventual placement of the product line on the store shelves.
Relevium has launched an initial four SKUs comprised of exclusive formulations from some of the highest volume sellers in the Bioganix product line. Management plans to issue an update on the initial performance in the second quarter and we expect this to be a catalyst for the company as it continues to grow its revenues.
We are favorable on this aspect of the story and consider it to be a value driver for Relevium. The company has been focused on executing on a multi-faceted growth strategy and has been producing solid revenues.
Relevium Expands Reach and Secures Strategic Partner
Last month, Relevium signed a supply agreement with Plena Global Holdings for full spectrum CBD oil to be used by the company’s supply chain partners in Europe starting January. Although this was a significant announcement for Relevium’s reach, the market did not seem impressed and the shares have been trending lower.
This agreement represents a significant opportunity as it will improve brand awareness and create a new revenue stream for the company. Relevium has already defined an initial product line and is in the process of finalizing formulations of its first CBD based nutraceuticals for the European Market.
Relevium is leveraging its current market expansion initiatives into the Europe to accelerate the introduction of CBD based nutraceutical supplements in this burgeoning market. The agreement with Plena is significant as it ensures a steady supply of superior quality full spectrum CBD oil for the company’s nutraceutical retail brands currently being launched in Europe
An Emerging Vertically Integrated Organic Medical Cannabis Producer
In addition to its core Health and Wellness business, Relevium is also focused on the production of organic cannabinoids for medical purposes through its wholly-owned subsidiary, Biocannabix (BCX). BCX is pursuing a cultivation and dealers license through Health Canada’s ACMPR application process and will be leveraging PipeDreemz and lead consultant George Routhier who has a remarkable 100% success rate with ACMPR licensing from Health Canada.
In June, BCX selected a 93,000 sq. ft. facility in Montreal to cultivate premium organic medical cannabis and to produce nutraceutical products. The building was selected due to its strategic location when it comes to distribution to other provinces as well as to retailers and consumers in Quebec. The building is next to the TransCanada Highway, Trudeau International Airport and about 20 minutes from downtown Montréal.
Relevium intends to develop the project in stages and expects to retrofit the building with an initial phase of 10,000 sq. ft. of cultivation. Upon the completion of the first stage, successful operations and licensing, the company will then proceed with phases 2 and 3. Construction of the project is subject to financing and customary approvals.
We are favorable on the focus on organic cannabis and on medical consumer products including nutraceuticals. This provides the company with a major differentiator and will help them secure shelf space. We are monitoring how the team continues to execute and consider this to be a major growth driver for the Canadian cannabis producer.
A Company to Watch
Relevium is an emerging opportunity and we are favorable on the potential catalysts for growth. The company is already generating strong revenues and Bioganix generated $1 million in revenue during the last quarter. We expect fundamentals to improve and strengthen and will keep an eye on this trend.
In mid-June, Relevium reported a milestone and commenced production of 920,000 soft-gels of its Cardio-Metabolic Syndrome and Dry-Eye Syndrome. In late 2017, Relevium announced an exclusivity agreement with Tersus Life Sciences to formulate and distribute exclusive products with Provinal Omega 7. The products will be marketed by BioGanix Platinum and Bioganix Gold labels and sold online through Amazon, Walmart and Native Website.
Relevium has been focused on developing new products, entering new markets, and securing strategic relationships for distribution. We are favorable on this focus and will monitor how the shares trade from here. Although the company has been executing, the shares have been trading lower with the market and this is a stock to watch.